tirzepatide gip/glp-1 drops GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Weight Management & Slimming -
Description
The discovery offers an explanation for why [...]
Pfizer is developing a long-acting GLP-1 drug that could compete directly with Eli Lilly's Mounjaro and Zepbound when it reaches the Canadian market.
Moridpour AH, Kavyani Z, Khosravi S, Farmani E, Daneshvar M, Musazadeh V, Faghfouri AH
Not for resale, redistribution, or template bundle re-packaging
GLP-1
